Opioid-induced constipation treatment market to boom to $650 mn by 2019

Majority of sales will come from the US, which will represent approximately 86% of the total market in 2019


(Photo Courtesy: www.medscape.com)

The opioid-induced constipation treatment market across the six major countries of the US, Germany, France, Italy, Spain and the UK will increase from an estimated $66.7 million in 2014 to $652.4 million by 2019, representing a rapid Compound Annual Growth Rate (CAGR) of 57.8%, according to research and consulting firm GlobalData.

The company's latest report states that the rising number of opioid-induced constipation sufferers is largely down to overall population increase and the continued use of opioids in the treatment of chronic non-cancer pain, which is driving impressive market growth.

Dr Claire Gibson, GlobalData's Analyst covering Cardiovascular and Metabolic Disorders, says that the introduction of novel targeted oral therapies for opioid-induced constipation, such as peripherally-acting mu-opioid receptor antagonists (PAMORAs), will be a major driver of market growth during the forecast period.

Dr Gibson explains: "While there is currently only one approved PAMORA, AstraZeneca's Movantik, the anticipated approval of another four PAMORAs in the US and Europe during the forecast period will mark a shift in the way that drugs for opioid-induced constipation are prescribed.

"Although laxatives are likely to remain the first-line therapy, the advent of these highly-targeted drugs will increase the number of patients receiving non-laxative prescription treatments for opioid-induced constipation."


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email